Fundamentals Overview
Thermo Fisher Scientific Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.
Valuation premium
Intrinsic value (DCF)
-1.9% downside vs price
Profitability
Risk (Beta)
0.87 — in line vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Analyst grade: B · Sentiment improving (4 upgrades)
Pressures (Sell):
3M vs S&P 500: -5.7%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 9, Hold: 1, Neutral: 2, Outperform: 5, Overweight: 13.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $524.12; current price is $534.07. That’s a -1.9% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 29.04 |
| DCF value (model) | $524.12 (-1.9% vs price) |
| PEG (TTM) | 5.5 |
| P/B (TTM) | 3.83 |
| P/S (TTM) | 4.39 |
| P/FCF (TTM) | 29.41 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 1.53 |
| Quick Ratio (TTM) | 1.15 |
| Cash Ratio (TTM) | 0.22 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 15.18% |
| Gross margin (TTM) | 39.41% |
| Operating margin (TTM) | 17.76% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for TMO.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-07-06 |
| HSBC | downgrade | Buy | Hold | 2026-06-03 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-05-08 |
| Stifel | maintain | Buy | Buy | 2026-04-24 |
| Baird | maintain | Outperform | Outperform | 2026-04-24 |
| Barclays | maintain | Overweight | Overweight | 2026-04-14 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-04-06 |
| Barclays | maintain | Overweight | Overweight | 2026-01-30 |
| TD Cowen | maintain | Buy | Buy | 2026-01-30 |
| Citigroup | maintain | Buy | Buy | 2026-01-30 |
| Stifel | maintain | Buy | Buy | 2026-01-09 |
| TD Cowen | maintain | Buy | Buy | 2026-01-07 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-12-15 |
| Citigroup | upgrade | Neutral | Buy | 2025-12-11 |
| Keybanc | upgrade | Sector Weight | Overweight | 2025-12-08 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-12-02 |
| HSBC | upgrade | Hold | Buy | 2025-12-01 |
| Argus Research | maintain | Buy | Buy | 2025-10-29 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-10-28 |
| Barclays | maintain | Overweight | Overweight | 2025-10-23 |
| UBS | maintain | Neutral | Neutral | 2025-10-23 |
| TD Cowen | maintain | Buy | Buy | 2025-10-23 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-10-23 |
| Citigroup | maintain | Neutral | Neutral | 2025-10-23 |
| Leerink Partners | maintain | Outperform | Outperform | 2025-10-22 |
| JP Morgan | maintain | Overweight | Overweight | 2025-10-09 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2025-10-07 |
| Barclays | maintain | Overweight | Overweight | 2025-10-02 |
| Barclays | upgrade | Equal Weight | Overweight | 2025-09-11 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-07-24 |